Critical Analysis: Celsion (CLSN) & Jaguar Health (JAGX)

Share on StockTwits

Jaguar Health (NASDAQ: CLSN) and Celsion (NASDAQ:CLSN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Jaguar Health and Celsion, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jaguar Health 0 0 0 0 N/A
Celsion 0 0 2 0 3.00

Celsion has a consensus target price of $8.00, suggesting a potential upside of 180.70%. Given Celsion’s higher possible upside, analysts plainly believe Celsion is more favorable than Jaguar Health.

Risk & Volatility

Jaguar Health has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500. Comparatively, Celsion has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.


This table compares Jaguar Health and Celsion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jaguar Health -664.21% -116.49% -48.97%
Celsion -4,479.42% -109.99% -49.22%

Earnings and Valuation

This table compares Jaguar Health and Celsion’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jaguar Health $4.36 million 9.94 -$21.96 million N/A N/A
Celsion $500,000.00 101.18 -$20.40 million ($2.39) -1.19

Celsion has lower revenue, but higher earnings than Jaguar Health.

Insider and Institutional Ownership

31.1% of Jaguar Health shares are owned by institutional investors. Comparatively, 4.8% of Celsion shares are owned by institutional investors. 4.7% of Jaguar Health shares are owned by company insiders. Comparatively, 2.4% of Celsion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Celsion beats Jaguar Health on 6 of the 11 factors compared between the two stocks.

About Jaguar Health

Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.

Leave a Reply